Moreover, a pilot clinical trial wherein 11 patients with Her2− metastatic breast cancer were treated with daily subcutaneous Anakinra for a median duration of 4 months, in combination with one of the standard chemotherapeutics, demonstrated that high risk Her2− breast cancer patients would benefit from reducing levels of IL-1β and treatment with anakinra (45, 46). This evidence concerns the gene IL1B and breast carcinoma.